1088 related articles for article (PubMed ID: 26731756)
1. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
[TBL] [Abstract][Full Text] [Related]
2. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Campos-Varela I; Moreno A; Morbey A; Guaraldi G; Hasson H; Bhamidimarri KR; Castells L; Grewal P; Baños I; Bellot P; Brainard DM; McHutchison JG; Terrault NA
Aliment Pharmacol Ther; 2016 Jun; 43(12):1319-29. PubMed ID: 27098374
[TBL] [Abstract][Full Text] [Related]
3. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
4. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
Grottenthaler JM; Werner CR; Steurer M; Spengler U; Berg T; Engelmann C; Wedemeyer H; von Hahn T; Stremmel W; Pathil A; Seybold U; Schott E; Blessin U; Sarrazin C; Welker MW; Harrer E; Scholten S; Hinterleitner C; Lauer UM; Malek NP; Berg CP
PLoS One; 2018; 13(6):e0197544. PubMed ID: 29874250
[TBL] [Abstract][Full Text] [Related]
5. IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting.
Londoño MC; Manzardo C; Rimola A; Ruiz P; Costa J; Forner A; Ambrosioni J; Agüero F; Laguno M; Lligoña A; Moreno A; Miró JM
J Antimicrob Chemother; 2016 Nov; 71(11):3195-3201. PubMed ID: 27402009
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation: Results From the ANRS CO23 CUPILT Study.
Antonini TM; Coilly A; Rossignol E; Fougerou-Leurent C; Dumortier J; Leroy V; Veislinger A; Radenne S; Botta-Fridlund D; Durand F; Houssel-Debry P; Kamar N; Canva V; Perré P; De Ledinghen V; Rohel A; Diallo A; Taburet AM; Samuel D; Pageaux GP; Duclos-Vallée JC;
Transplantation; 2018 Jan; 102(1):119-126. PubMed ID: 28846559
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
[TBL] [Abstract][Full Text] [Related]
8. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
9. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience.
Yosry A; Gamal Eldeen H; Medhat E; Mehrez M; Zayed N; Elakel W; Abdelmoniem R; Kaddah M; Abdelaziz A; Esmat G; El-Serafy M; Doss W
J Med Virol; 2019 Apr; 91(4):668-676. PubMed ID: 30549048
[TBL] [Abstract][Full Text] [Related]
11. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.
Manzardo C; Londoño MC; Castells L; Testillano M; Luis Montero J; Peñafiel J; Subirana M; Moreno A; Aguilera V; Luisa González-Diéguez M; Calvo-Pulido J; Xiol X; Salcedo M; Cuervas-Mons V; Manuel Sousa J; Suarez F; Serrano T; Ignacio Herrero J; Jiménez M; Fernandez JR; Giménez C; Del Campo S; Esteban-Mur JI; Crespo G; Moreno A; de la Rosa G; Rimola A; Miro JM;
Am J Transplant; 2018 Oct; 18(10):2513-2522. PubMed ID: 29963780
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
Faisal N; Bilodeau M; Aljudaibi B; Hirsch G; Yoshida EM; Hussaini T; Ghali MP; Congly SE; Ma MM; Leonard J; Cooper C; Peltekian K; Renner EL; Lilly LB
Transplantation; 2016 May; 100(5):1059-65. PubMed ID: 26950722
[TBL] [Abstract][Full Text] [Related]
13. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
Leroy V; Dumortier J; Coilly A; Sebagh M; Fougerou-Leurent C; Radenne S; Botta D; Durand F; Silvain C; Lebray P; Houssel-Debry P; Kamar N; D'Alteroche L; Petrov-Sanchez V; Diallo A; Pageaux GP; Duclos-Vallee JC;
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1993-2001.e1-2. PubMed ID: 26044317
[TBL] [Abstract][Full Text] [Related]
15. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
Donato MF; Morelli C; Romagnoli R; Invernizzi F; Mazzarelli C; Iemmolo RM; Montalbano M; Lenci I; Bhoori S; Pieri G; Berardi S; Caraceni P; Martini S;
Liver Int; 2017 May; 37(5):678-683. PubMed ID: 27865034
[TBL] [Abstract][Full Text] [Related]
16. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
Rockstroh JK; Ingiliz P; Petersen J; Peck-Radosavljevic M; Welzel TM; Van der Valk M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
Antivir Ther; 2017; 22(3):225-236. PubMed ID: 27845298
[TBL] [Abstract][Full Text] [Related]
17. Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.
Del Bello D; Cha A; Sorbera M; Bichoupan K; Levine C; Doyle E; Harty A; Patel N; Ng M; Gardenier D; Odin J; Schiano TD; Fierer DS; Berkowitz L; Perumalswami PV; Dieterich DT; Branch AD
Clin Infect Dis; 2016 Jun; 62(12):1497-1504. PubMed ID: 26936665
[TBL] [Abstract][Full Text] [Related]
18. 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Luetkemeyer AF; McDonald C; Ramgopal M; Noviello S; Bhore R; Ackerman P
Clin Infect Dis; 2016 Jun; 62(12):1489-96. PubMed ID: 27025835
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
Jackson WE; Hanouneh M; Apfel T; Alkhouri N; John BV; Zervos X; Zein NN; Hanouneh IA
Clin Transplant; 2016 Jun; 30(6):709-13. PubMed ID: 27019204
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.
Gutierrez JA; Carrion AF; Avalos D; O'Brien C; Martin P; Bhamidimarri KR; Peyton A
Liver Transpl; 2015 Jun; 21(6):823-30. PubMed ID: 25825070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
